

April 29, 2019

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,

Sub: Audited Financial Results for the quarter and year ended March 31, 2019


Pursuant to Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Audited Financial Results for the quarter and year ended March 31, 2019 which were approved by the Board of Directors of the Company, at its meeting held on April 29, 2019 along with Auditors Report with unmodified opinion thereon.

The meeting commenced at 3.30 p.m. and concluded at 7.00 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head – Legal & Company Secretary



Encl: As above

April 29, 2019

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sirs,


Sub: Declaration pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of the provisions of Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby state that the Statutory Auditor of the Company M/s. B S R & Co. LLP (Firm's Registration No. 101248WWW-100022) have issued an Audit Report with unmodified opinion on the Audited Financial Results of the Company for the year ended March 31, 2019.

Kindly take this declaration on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited


Manesh Narayanaswamy
Vice President - Finance



B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Independent Auditor's Report on the Financial Results of RPG Life Sciences Limited Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

The Board of Directors of RPG Life Sciences Limited

We have audited the annual financial results of RPG Life Sciences Limited ('the Company') for the year ended 31 March 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Attention is drawn to the fact that figures for the last quarter ended 31 March 2019 and the corresponding quarter ended in the previous year as reported in these annual financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures up to the end of the third quarter had only been reviewed and not subjected to audit.

These annual financial results have been prepared on the basis of the annual financial statements and reviewed quarterly financial results which are the responsibility of the Company's Management. Our responsibility is to express an opinion on these annual financial results based on our audit of the annual financial statements which have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules, 2015 as per Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the annual financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by Management. We believe that our audit provides a reasonable basis for our opinion.

**Independent Auditor's Report on the Financial Results of RPG Life Sciences Limited Pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
(Continued)**

RPG Life Sciences Limited

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view of the net profit and other comprehensive income and other financial information for the year ended 31 March 2019.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No. 101248W/W- 100022



Bhavesh Dhupelia
Partner
Membership No. 042070

Mumbai
29 April 2019

Statement of Financial Results for the quarter and year ended 31st March 2019

(Rs. in Lakhs)

Particulars	Quarter ended			Year ended	
	31-Mar-19	31-Dec-18	31-Mar-18	31-Mar-19	31-Mar-18
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1 Revenue from Operations	6,880	9,097	8,346	33,016	34,714
2 Other Income	42	2	32	80	98
3 Total Income	6,922	9,099	8,378	33,096	34,812
4 Expenses					
(a) Cost of Materials Consumed	953	1,459	2,237	5,117	7,195
(b) Purchases of Stock-in-Trade	1,212	1,132	1,364	4,516	4,935
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	159	336	(852)	1,371	(669)
(d) Excise Duty	-	-	-	-	319
(e) Employee Benefits Expense	1,991	2,394	2,487	8,993	9,014
(f) Finance Costs	91	99	83	399	380
(g) Depreciation and Amortisation Expense	394	386	368	1,532	1,434
(h) Other Expenses	1,910	2,568	2,252	9,663	10,168
Total Expenses	6,710	8,374	7,939	31,591	32,776
5 Profit before tax	212	725	439	1,505	2,036
6 Income tax expenses					
a. Current Tax	18	120	88	284	385
b. Deferred Tax	40	77	226	140	306
7 Profit for the period	154	528	125	1,081	1,345
8 Other Comprehensive Income					
(i) Items that will not be reclassified to Profit or Loss	(23)	(6)	47	(41)	(22)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	8	2	8	14	8
Other Comprehensive Income Net of Tax	(15)	(4)	55	(27)	(14)
9 Total Comprehensive Income for the period	139	524	180	1,054	1,331
10 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323
11 Other Equity				14,727	14,152
12 Total Earning per Share from operations (of Rs. 8/- each) (not annualised):					
(a) Basic	0.93	3.19	0.76	6.54	8.13
(b) Diluted	0.93	3.19	0.76	6.54	8.13



Statement of Assets and Liabilities as at March 31, 2019

(Rs. in Lakhs)

Particulars	As at 31st March 2019	As at 31st March 2018
	(Audited)	
ASSETS		
Non-current assets		
Property, plant and equipment	8,251	7,994
Capital work-in-progress	1,012	480
Other intangible assets	4,513	5,086
Intangible assets under development	705	393
Financial assets		
ii. Loans	10	9
iii. Other financial assets	30	28
Deferred tax assets (Net)	618	744
Current Tax asset	125	57
Other non-current assets	151	74
Total non-current assets	15,415	14,865
Current assets		
Inventories	4,104	5,369
Financial assets		
i. Trade receivables	3,890	6,813
ii. Cash and cash equivalents	37	11
iii. Bank balances other than (ii) above	40	83
iv. Other financial assets	96	110
Other current assets	1,542	1,876
Total current assets	9,709	14,262
Total assets	25,124	29,127
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,323	1,323
Other equity		
Reserves and Surplus	14,727	14,152
Total equity	16,050	15,475
LIABILITIES		
Non-current liabilities		
Financial liabilities		
i. Borrowings	658	1,023
i. Other financial liabilities	299	279
Provisions	335	279
Total non-current liabilities	1,292	1,581
Current liabilities		
Financial liabilities		
i. Borrowings	2,904	3,792
ii. Trade payables		
-Total Outstanding Dues of Micro Enterprises and Small Enterprises	-	-
-Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises		
iii. Other financial liabilities	2,513	5,187
Provisions	823	1,503
Current tax liabilities (Net)	1,033	1,225
Other current liabilities	-	20
Total current liabilities	509	344
Total liabilities	7,782	12,071
Total equity and liabilities	9,074	13,652
	25,124	29,127



Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 29, 2019.
- 2 Figures for the quarter ended March 31, 2019 and the corresponding quarter ended in the previous year as reported in the financial result are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- 3 The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- 4 The Government of India introduced the Goods and Service Tax ('GST') from July 1, 2017, consequently the revenue from operations for the quarters ended March 31, 2019, December 31, 2018 and March 31, 2018 are reported net of GST. However revenue for all other periods presented is inclusive of excise duty, where applicable. The Net Revenue from operations (Net of GST/Excise Duty) as applicable are stated below:

Particulars	Quarter ended			Year ended	
	31-Mar-19	31-Dec-18	31-Mar-18	31-Mar-19	31-Mar-18
Revenue from Operations	6,880	9,097	8,346	33,016	34,714
Less: Excise Duty	-	-	-	-	319
Net Revenue from operations	6,880	9,097	8,346	33,016	34,395

- 5 The Board of Directors has recommended a normal dividend of Rs. 2.40 per share of Rs 8/- each. (30%) for the year ended March 31, 2019, subject to the approval of members at the ensuing Annual General Meeting.
- 6 The MCA vide notification dated October 11, 2018 has amended Schedule III to the Companies Act, 2013 in respect of certain disclosure. The Company has incorporated appropriate changes in the above results.

For RPG Life Sciences Limited


 Yugul Sikri
 Managing Director
 Mumbai, April 29, 2019

